GeoMx Cancer Transcriptome Atlas (CTA)
The Cancer Transcriptome Atlas (CTA) is designed for comprehensive profiling of the tumor biology, tumor microenvironment, and the immune response. It covers the RNA expression of over 1,800 genes simultaneously with spatial resolution in any region of interest from a single tissue section.


  • Extensive coverage of the immune response, tissue microenvironment, tumor biology, and genes from clinically relevant genes sets such as tumor inflammation

  • Spatial measurement of single cell signatures with high sensitivity and dynamic range

  • Inclusion of genes for the Tumor Inflammation Signature, PAM50 and other clinical signatures

  • Over 100 pathways to explore all aspects of cancer and tumor biology



The CTA assay is compatible with RNAscope® and antibody visualization markers. It can also be supplemented with up to 60 additional targets of interest.

Learn about out spatial transcriptomics services


Comprehensively Annotated Pathways in the CTA

































































































































































































Adaptive Immunity  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
Cell Function  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 
Signaling Pathways
T cells B cells Apoptosis AMPK Signaling
TCR & BCR Signaling Autophagy Androgen Signaling
Cancer Antigens Cell Adhesion & Motility EGFR Signaling
MHC Class I & II Antigen Presentation Cell Cycle ERBB2 Signaling
T-cell Checkpoints Cilium Assembly Estrogen Signaling
TH1, TH2, TH9, Th17, and Treg Differentiation Differentiation FGFR Signaling
DNA Damage Repair FoxO Signaling
Innate Immunity EMT GPCR Signaling
Complement System Endocytosis Hedgehog Signaling
Dendritic Cells Epigenetic Modification HIF1 Signaling
DNA & RNA Sensing Immortality & Stemness Insulin Signaling
Glycan Sensing Ion Transport JAK-STAT Signaling
Host Defense Peptides Lysosome MAPK Signaling
Inflammasomes Oxidative Stress MET Signaling
Myeloid Inflammation Phagocytosis mTOR Signaling
Neutrophil Degranulation Proteotoxic Stress Myc
NK Activity RNA Processing NO Signaling
NLR Signaling Senescence Notch Signaling
RAGE Signaling p53 Signaling
TLR Signaling Metabolism PDGF Signaling
Amino Acid Synthesis & Transport PI3K-Akt Signaling
Immune Response Arginine & Glutamine Metabolism PPAR Signaling
Chemokine Signaling Fatty Acid Oxidation & Synthesis Purinergic Signaling
Cytotoxicity Glycolysis & Glucose Transport Retinoic Acid Signaling
IL-1, IL-2, IL-6 & IL-17 Signaling Glycosylation TGF-beta Signaling
Immune Exhaustion IDH1/2 VEGF Signaling
Interferon Response Genes Lipid Metabolism Wnt Signaling
Lymphocyte Regulation & Trafficking Mitochondrial Metabolism / TCA
NF-kB Signaling Nucleotide Synthesis Physiology & Disease
Other Interleukin Signaling Pentose Phosphate Angiotensin System
Prostaglandin Inflammation Tryptophan & Kynurenine Metabolism Circadian Clock
TNF Signaling Vitamin & Cofactor Metabolism Drug Resistance
Type I, II, & III Interferon Signaling  

 

 

 

 

 
Glioma
 

 

 

 

 
Leukemia
Matrix Remodeling and Metastasis
Melanoma
Neuroendocrine Function
Prostate Cancer


chicago asco
From June 3 to 7, 2022, we will be setting up our quarters in Chicago for the American Society of Clinical Oncology Annual Meeting to continue gaining the latest insights in research and clinical development in Oncology. Also, our CEO Dr. Alban Bessede will have the great opportunity to present a scientific poster highlighting our recent advances in biomarker research in Immuno-Oncology.
MCA-205
Soft Tissue Sarcoma (STS) is known to be refractory to current cancer immunotherapies including the PD1 immune checkpoint inhibitor (ICI) (Toulmonde et al., 2018), thus claiming the development of novel therapeutic strategies aiming at improving the current clinical benefit.
WordPress Lightbox